Fluoxetine
selective serotonin reuptake inhibitor invented by Eli Lilly and Company in 1972
Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class used for the treatment of major depressive disorder, anxiety, obsessive–compulsive disorder (OCD), panic disorder, premenstrual dysphoric disorder, and bulimia nervosa. It is also approved for treatment of major depressive disorder in adolescents and children eight years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth.
Common side effects of fluoxetine include loss of appetite, nausea, diarrhea, headache, trouble sleeping, dry mouth, and sexual dysfunction. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction. Serious side effects include serotonin syndrome, mania, seizures, an increased risk of suicidal behavior, and an increased risk of bleeding.
Fluoxetine was invented by Eli Lilly and Company in 1972. Eli Lilly filed a new drug application for the US Food and Drug Administration in 1974, which was accepted in 1977. It subsequently entered medical use in 1986.
The public source identifies “Fluoxetine” as selective serotonin reuptake inhibitor invented by Eli Lilly and Company in 1972. This brief keeps that definition visible, then builds a research path around Fluoxetine, selective and serotonin.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Fluoxetine”, the useful work is to connect “selective serotonin reuptake inhibitor invented by Eli Lilly and Company in 1972” to the records capable of establishing context and consequence.
Chronology, provenance and viewpoint should be read together before a broad social or political interpretation is accepted. The source revision retrieved here is dated Sep 7, 2026. The linked authority identifier is Q422244. The Library of Congress control number is sh90005418. 1 of 1 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 1972, 1974, 1977 and 1986.
Official terminology may obscure informal participation, dissent or communities documented only indirectly. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Fluoxetine”, its source revision and the description used here.
- Expand the search: follow Fluoxetine primary sources, Fluoxetine archive and Fluoxetine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Fluoxetine”?
- Which voices are present, absent or mediated by the institution?
- What chronology connects this entry to wider political or social change?
Search terms from this dossier
This entry incorporates text from “Fluoxetine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.